BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15075621)

  • 1. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development.
    De Vry J; Jentzsch KR; Kuhl E; Eckel G
    Behav Pharmacol; 2004 Feb; 15(1):1-12. PubMed ID: 15075621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm.
    De Vry J; Jentzsch KR
    Behav Pharmacol; 2004 Feb; 15(1):13-20. PubMed ID: 15075622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.
    Fan F; Compton DR; Ward S; Melvin L; Martin BR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1383-90. PubMed ID: 7996450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
    Pertwee RG; Stevenson LA; Griffin G
    Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.
    McMahon LR
    Br J Pharmacol; 2011 Mar; 162(5):1060-73. PubMed ID: 21091643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR
    Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.
    Lauckner JE; Hille B; Mackie K
    Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19144-9. PubMed ID: 16365309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
    Fox A; Kesingland A; Gentry C; McNair K; Patel S; Urban L; James I
    Pain; 2001 May; 92(1-2):91-100. PubMed ID: 11323130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice.
    Darmani NA
    Pharmacol Biochem Behav; 2001 Feb; 68(2):311-7. PubMed ID: 11267636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat.
    De Vry J; Jentzsch KR
    Eur J Pharmacol; 2004 Nov; 505(1-3):127-33. PubMed ID: 15556145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats.
    Solinas M; Panlilio LV; Tanda G; Makriyannis A; Matthews SA; Goldberg SR
    Neuropsychopharmacology; 2005 Nov; 30(11):2046-57. PubMed ID: 15870833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
    Romero J; Berrendero F; García-Gil L; Ramos JA; Fernández-Ruiz JJ
    J Mol Neurosci; 1998 Oct; 11(2):109-19. PubMed ID: 10096037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.
    Wiley JL; Barrett RL; Lowe J; Balster RL; Martin BR
    Neuropharmacology; 1995 Jun; 34(6):669-76. PubMed ID: 7566504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.
    Martin BR; Compton DR; Thomas BF; Prescott WR; Little PJ; Razdan RK; Johnson MR; Melvin LS; Mechoulam R; Ward SJ
    Pharmacol Biochem Behav; 1991 Nov; 40(3):471-8. PubMed ID: 1666911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
    Oviedo A; Glowa J; Herkenham M
    Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Internalization and recycling of the CB1 cannabinoid receptor.
    Hsieh C; Brown S; Derleth C; Mackie K
    J Neurochem; 1999 Aug; 73(2):493-501. PubMed ID: 10428044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ; Martin BR
    J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
    Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
    Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pronociceptive effects of spinal dynorphin promote cannabinoid-induced pain and antinociceptive tolerance.
    Gardell LR; Burgess SE; Dogrul A; Ossipov MH; Malan TP; Lai J; Porreca F
    Pain; 2002 Jul; 98(1-2):79-88. PubMed ID: 12098619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.